Bioorganic and Medicinal Chemistry Letters p. 2216 - 2220 (2017)
Update date:2022-08-04
Topics:
Salvino, Joseph M.
Srikanth, Yellamelli V.V.
Lou, Rongliang
Oyer, Halley M.
Chen, Nan
Kim, Felix J.
Prostate cancer is the most frequently diagnosed malignancy and the leading cause of cancer related death in men. First line therapy for disseminated disease relies on androgen deprivation, leveraging the addiction of these tumors on androgens for both growth and survival. Treatment typically involves antagonizing the androgen receptor (AR) or blocking the synthesis of androgens. Recurrence is common and within 2–3?years patients develop castration resistant tumors that become unresponsive to AR-axis targeted therapies. In order to provide a more effective treatment, we are utilizing an approach that targets a key scaffolding protein, Sigma1 (also known as sigma-1 receptor), a unique 26-kilodalton integral membrane protein that is critical in stabilizing the AR. Herein we report on a new series of Sigma1 compounds for lead optimization derived from a hybrid pharmacophore approach.
View MoreContact:+1-973-357-0577
Address:10 Taft Rd.
Triumph International Development Limilted
website:http://www.jiashengchem.cn/
Contact:+86-536-7971999
Address:Yinhai Road,Shouguang
Nanjing Spring & Autumn Biological Engineering Co., Ltd.
Contact:86-180510-83338
Address:Suite# 210, No. 1 BuildingNanjing Agricultural Biotechnology High-tech Entrepreneurship Center, No. 4 Tongwei Road, Xuanwu District, Nanjing,China
Wuhan Konberd Biotech Co., Ltd.
Contact:+86-27-87205925
Address:NO.666, Gaoxin Road, Eastlake High-tech zone
Nanjing Samwon International Limited
Contact:+86-25-84873444
Address:1108, BLDG B, New Century Plaza, No 1, South Taiping Rd.,
Doi:10.1016/j.tetlet.2014.01.010
(2014)Doi:10.1021/jo402658h
(2014)Doi:10.1002/hc.10129
(2003)Doi:10.1021/om00031a009
(1993)Doi:10.3762/bjoc.14.92
(2018)Doi:10.1039/DT9950000409
(1995)